The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension - Trial NCT05948644
Access comprehensive clinical trial information for NCT05948644 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vigonvita Life Sciences and is currently Completed. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vigonvita Life Sciences
Timeline & Enrollment
Phase 1
Apr 08, 2019
Oct 14, 2020
Primary Outcome
Incidence of Treatment-Emergent Adverse Events,Q-T interval,Tmax,Cmax,AUC0~t,AUC0-∞,Terminal half-life (t 1/2),Apparent distribution volume (Vd/F),Clearance rate (CL/F),Mean Residence Time(MRT)
Summary
Exploring the safety, tolerability, and pharmacokinetic (PK) characteristics of oral TPN171H
 tablets in patients with Pulmonary Arterial Hypertension under continuous multiple
 administration conditions, providing a basis for determining the administration plan and
 recommended dosage in phase II clinical study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05948644
Non-Device Trial